恶性肿瘤相关噬血综合征的研究进展

秦琼; 钟殿胜

doi:10.12354/j.issn.1000-8179.2023.20221142

恶性肿瘤相关噬血综合征的研究进展

doi: 10.12354/j.issn.1000-8179.2023.20221142

秦琼,
钟殿胜^,

天津医科大学总医院肿瘤内科（天津市300052）

详细信息

作者简介:
秦琼：专业方向为恶性肿瘤的综合治疗

通讯作者:
钟殿胜　zhongdsh@hotmail.com

计量
- 文章访问数: 271
- HTML全文浏览量: 56
- PDF下载量: 67
- 被引次数: 0
出版历程
- 收稿日期: 2022-08-04
- 录用日期: 2022-10-26
- 修回日期: 2022-09-27
- 网络出版日期: 2022-11-03

Research progress on malignancy-associated hemophagocytic lymphohistiocytosis

Qiong Qin,
Diansheng Zhong^,

Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China

More Information

Corresponding author: Diansheng Zhong；E-mail: zhongdsh@hotmail.com

摘要

摘要: 噬血综合征（hemophagocytic lymphohistiocytosis，HLH）是一种少见的疾病，由于机体分泌大量细胞因子产生过度炎症反应，进而导致多器官、多系统受累的临床综合征。恶性肿瘤相关噬血综合征（malignancy-associated hemophagocytic lymphohistiocytosis，MA-HLH）患者多数病情危重、误诊率、延诊率和死亡率较高，对其认识不断被重视和深化。尤其是在免疫检测点抑制剂的广泛应用之后，MA-HLH的发生越来越多。本文结合近年来这一领域相关研究进展，从流行病学、易患因素、病理生理、诊断标准及治疗等方面进行综述。
- 恶性肿瘤 /
- 噬血综合征 /
- 诊断 /
- 治疗
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease characterized by uncontrolled cytotoxic T cells and macrophages. Contributing causes include heredity, infection, autoimmune disease, and tumors, which stimulate the activation of macrophages and secretion of a large number of inflammatory factors. Most malignancy-associated hemophagocytic lymphohistiocytosis (MA-HLH) patients are in critical condition at time of diagnosis, due a high rate of delayed diagnosis and misdiagnosis, resulting in highmortality. With extensive application of immune checkpoint inhibitors, incidence of MA-HLH is increasing. This article reviews recent research progress in this field, focused on epidemiology, predisposing factors, pathophysiology, diagnostic criteria, and treatment.
- malignancy /
- hemophagocytic lymphohistiocytosis (HLH) /
- diagnosis /
- treatment

HTML全文

参考文献(36)

[1]	Setiadi A, Zoref-Lorenz A, Lee CY, et al. Malignancy-associated haemophagocyticlymphohistiocytosis[J]. Lancet Haematol, 2022, 9(3):e217-e227. doi: 10.1016/S2352-3026(21)00366-5
[2]	Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome[J]. Lancet, 2014, 383(9927):1503-1516.
[3]	Yoon SE, Eun Y, Huh K, et al. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study[J]. Ann Hematol, 2020, 99(9):2095-2104. doi: 10.1007/s00277-020-04083-6
[4]	Tamamyan GN, Kantarjian HM, Ning J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes[J]. Cancer, 2016, 122(18):2857-2866.
[5]	Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks[J]. Blood, 2018, 132(15):1561-1567. doi: 10.1182/blood-2017-04-737445
[6]	El-Mallawany NK, Curry CV, Allen CE. Haemophagocyticlymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes[J]. Br J Haematol, 2022, 196(1):31-44. doi: 10.1111/bjh.17638
[7]	La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23):2465-2477. doi: 10.1182/blood.2018894618
[8]	Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease[J]. Blood,2011, 117(1):53-62.
[9]	Li FY, Chaigne-Delalande B, Su H, et al. XMEN disease: a new primary immunodeficiency affecting Mg²⁺ regulation of immunity against Epstein-Barr virus[J]. Blood, 2014, 123(14):2148-2152. doi: 10.1182/blood-2013-11-538686
[10]	Gayden T, Sepulveda FE, Khuong-Quang DA, et al. Author correction: germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome[J]. Nat Genet, 2019, 51(1):196.
[11]	Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management[J]. Paediatr Drugs, 2020, 22(1):29-44.
[12]	Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocyticlymphohistiocytosis in children and adolescents[J]. Br J Haematol, 2015, 170(4):539-549.
[13]	Hege K, Quigg T, Delgado D. Alemtuzumab, fludarabine, low-dose TBI, and double umbilical cord transplant for primary graft failure in a patient with recurrent HLH[J]. Pediatr Blood Cancer, 2016, 63(2):361-363. doi: 10.1002/pbc.25782
[14]	Delavigne K, Berard E, Bertoli S, et al. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy[J]. Haematologica, 2014, 99(3):474-480. doi: 10.3324/haematol.2013.097394
[15]	Noseda R, Bertoli R, Muller L, et al. Haemophagocyticlymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports[J]. J Immunother Cancer, 2019, 7(1):117-123.
[16]	Dupre A, Michot JM, Schoeffler A, et al. Haemophagocyticlymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review[J]. Br J Haematol, 2020, 189(5):985-992. doi: 10.1111/bjh.16630
[17]	Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells[J]. Blood, 2021, 138(24):2469-2484. doi: 10.1182/blood.2021011898
[18]	Jordan MB, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+T cells and interferon gamma are essential for the disorder[J]. Blood, 2004, 104(3):735-743.
[19]	Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2):124-131. doi: 10.1002/pbc.21039
[20]	Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66(9):2613-2620. doi: 10.1002/art.38690
[21]	Bilston L, Croden J, Taparia M, et al. Validation of the HScore and the HLH-2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort[J]. Eur J Haematol, 2022, 109(2):129-137. doi: 10.1111/ejh.13779
[22]	Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis[J]. Blood, 2022, 139(7):1098-1110. doi: 10.1182/blood.2021012764
[23]	Hines MR, Keenan C, Maron AG, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy[J]. Br J Haematol, 2021, 194(4):701-707. doi: 10.1111/bjh.17662
[24]	Tabata C, Tabata R. Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome[J]. Ann Hematol, 2012, 91(1):63-71.
[25]	Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH[J]. Blood Adv, 2017, 1(26):2529-2534.
[26]	Tudesq JJ, Valade S, Galicier L, et al. Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study[J]. Hematol Oncol, 2021, 39(1):114-122. doi: 10.1002/hon.2819
[27]	Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study[J]. Blood, 2017, 130(25):2728-2738. doi: 10.1182/blood-2017-06-788349
[28]	Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2015, 126(19):2186-2192. doi: 10.1182/blood-2015-05-644914
[29]	Marsh RA. Epstein-Barr virus and hemophagocytic lymphohistiocytosis[J]. Front Immunol, 2017, 8:1902.
[30]	Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis[J]. N Engl J Med, 2020, 382(19):1811-1822.
[31]	Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series[J]. Eur J Haematol, 2021, 106(5):654-661.
[32]	Zhou L, Liu Y, Wen Z, et al. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome[J]. J Cancer Res Clin Oncol, 2020, 146(11):3063-3074. doi: 10.1007/s00432-020-03301-y
[33]	Dufranc E, Del BA, Belliere J, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome[J]. Crit Care, 2020, 24(1):166. doi: 10.1186/s13054-020-02878-7
[34]	Liang JH, Wang L, Zhu HY, et al. Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase Ⅱ trial[J]. Haematologica, 2020, 105(1):e29-e32. doi: 10.3324/haematol.2019.220301
[35]	Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis[J]. QJM, 2018, 111(1):23-31. doi: 10.1093/qjmed/hcx183
[36]	Jin Z, Wang Y, Wang J, et al. Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis[J]. Hematology, 2018, 23(4):228-234. doi: 10.1080/10245332.2017.1385191